Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median 15.7 months, 13.1–17.8), with only a 23% response rate to monotherapy treatment with anti-PDL1 checkpoint immunotherapy. To identify new therapeutic targets, we profiled the immune regulatory signatur...

Descripción completa

Detalles Bibliográficos
Autores principales: Podojil, Joseph R., Glaser, Alexander P., Baker, Dylan, Courtois, Elise T., Fantini, Damiano, Yu, Yanni, Eaton, Valerie, Sivajothi, Santhosh, Chiang, Mingyi, Das, Arighno, McLaughlin, Kimberly A., Robson, Paul, Miller, Stephen D., Meeks, Joshua J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185218/
https://www.ncbi.nlm.nih.gov/pubmed/32363111
http://dx.doi.org/10.1080/2162402X.2020.1744897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185218/
https://www.ncbi.nlm.nih.gov/pubmed/32363111
http://dx.doi.org/10.1080/2162402X.2020.1744897

Ejemplares similares